Hollis-Eden Pharmaceuticals Inc. Presents Additional Positive Data With Novel Steroid Hormone In Models Of Prostate And Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today the presentation of additional positive data with the Company’s novel steroid compound HE3235 in preclinical models of hormone refractory prostate cancer (HRPC) and breast cancer. New data presented indicated HE3235 arrested the growth of established prostate tumors whereas placebo-treated animals continued to experience rapid tumor growth. In addition, data were presented indicating HE3235 reduced the tumor incidence and the tumor burden in a carcinogen induced breast cancer model. The results are being presented this week by Dr. Richard Trauger, Hollis-Eden’s Director of Infectious Diseases and Cancer, at the American Society for Clinical Oncology’s Prostate Cancer Symposium in Orlando Florida.